SCHEMBL14320503

SCHEMBL14320503

CS(=O)(=O)c1cccc(Nc2nc(-c3cccs3)nc3cn[nH]c23)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 7/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
ABCB1 P08183 2/20 0.46
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 2/20 0.46
MAPT P10636 2/20 0.46
HTT P42858 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
HPGD P15428 1/20 0.46
MAPK1 P28482 1/20 0.46
PDE5A O76074 1/20 0.44
CD38 P28907 1/20 0.42
ABCC1 P33527 1/20 0.41
SCD O00767 1/20 0.41
EPHB4 P54760 2/20 0.40
KDM1A O60341 2/20 0.39
GBA1 P04062 1/20 0.39
TNNI3K Q59H18 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14320531 0.90 TNNI3K (0.50) ABCG2MEN1KMT2AABCB1KDM4E
SCHEMBL14320706 0.90 ALDH1A1 (0.46) ABCG2MEN1KMT2AABCB1KDM4E
SCHEMBL14320741 0.88 ABCG2 (0.46) ABCG2MEN1KMT2AABCB1KDM4E
SCHEMBL14320528 0.86 ABCG2 (0.43) ABCG2MEN1KMT2AABCB1KDM4E
SCHEMBL14320555 0.85 CSNK2A1 (0.48) ABCG2MEN1KMT2AABCB1KDM4E
SCHEMBL14320698 0.85 PIK3CA (0.49) ABCG2MEN1KMT2AABCB1KDM4E
SCHEMBL14320387 0.83 KCNA5 (0.51) ALDH1A1L3MBTL1HPGDPDE5AGBA1
SCHEMBL14320853 0.83 ABCG2 (0.50) ABCG2MEN1KMT2AABCB1KDM4E
SCHEMBL14320493 0.82 ABCG2 (0.47) ABCG2MEN1KMT2AABCB1KDM4E
SCHEMBL14321188 0.80 ABCG2 (0.46) ABCG2MEN1KMT2AABCB1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US claimed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP claimed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US claimed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK ABCG2 3810/4885MEN1 544/4885KMT2A 921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.